Issuance of Letter to Stockholders

On January 29, 2018, Shawn Singh, Chief Executive Officer and Director of VistaGen Therapeutics, Inc. (the “Company”), sent a letter to the Company’s stockholders highlighting the Company’s recent milestones and discussing the impending launch of the Company’s Phase 2 clinical study of its lead product candidate, AV-101, for the adjunctive treatment of Major Depressive Disorder. A copy of the press release announcing Mr. Singh’s issuance of the letter is attached hereto as Exhibit 99.1, and a copy of Mr. Singh’s letter is attached hereto as Exhibit 99.2.

Use of New Corporate Presentation

On January 29, 2018, the Companyutilized a new corporate presentation (the “Corporate Presentation”) for business purposes. A copy of the Corporate Presentation is attached hereto as Exhibit99.3.

The information in this Current Report onForm8-K,including the information set forth in Exhibits99.1, 99.2 and 99.3 are being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall any exhibit filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.

See Exhibit Index.

VistaGen Therapeutics, Inc. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE ISSUED BY VISTAGEN THERAPEUTICS,…
To view the full exhibit click here

About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.